


AMENDMENTS TO THE CLAIMS

Applicant submits below a complete listing of the current claims, including marked-up claims with insertions indicated by underlining and deletions indicated by strikeouts and/or double bracketing. This listing of claims replaces all prior versions, and listings, of claims in the application:


1. (Canceled)
2. (Currently amended) A compound of the Formula (II):



II

wherein:

Z is -C(=N-O-R₁₋₂)- or



X is ~~selected from the group consisting of:~~

~~-CH(R₉)-[[,]~~

~~-CH(R₉)-alkylene-, and~~

~~-CH(R₉)-alkenylene-,~~

~~wherein the alkylene and alkenylene are optionally interrupted by one or more O-~~
~~groups;~~

R₁₋₁ is selected from the group consisting of:

hydrogen,

alkyl,

aryl,

alkylene-aryl,

heteroaryl,
alkylene-heteroaryl, and
alkyl, aryl, alkylene-aryl, heteroaryl, or alkylene-heteroaryl substituted by one or more substituents selected from the group consisting of:

halogen,
cyano,
nitro,
alkoxy,
dialkylamino,
alkylthio,
haloalkyl,
haloalkoxy,
alkyl,
-NH-SO₂-R₁₋₄,
-NH-C(O)-R₁₋₄,
-NH-C(O)-NH₂,
-NH-C(O)-NH-R₁₋₄, and
-N₃;


R₁₋₂ and R₁₋₃ are independently selected from the group consisting of:

hydrogen,
alkyl,
~~alkenyl~~,
~~aryl~~,
~~arylalkylenyl~~,
~~heteroaryl~~,
~~heteroarylalkylenyl~~,
~~heterocyclyl~~,
~~heterocyclylalkylenyl~~, and

~~alkyl, alkenyl, aryl, arylalkylenyl, heteroaryl, heteroarylalkylenyl, heterocyclyl, or heterocyclylalkylenyl,~~ substituted by one or more substituents selected from the group consisting of:

~~hydroxy,
alkyl,
haloalkyl,
hydroxyalkyl,
alkoxy,
dialkylamino,
-S(O)₀₋₂-alkyl,
-S(O)₀₋₂-aryl,
-NH-S(O)₂-alkyl,
-NH-S(O)₂-aryl,
haloalkoxy,
halogen,
cyano,
nitro,
aryl, and
heteroaryl[[,]];
heterocyclyl,
aryloxy,
arylalkyleneoxy,
-C(O)-O-alkyl,
-C(O)-N(R₈)₂,
-N(R₈)-C(O)-alkyl,
-O-(CO)-alkyl, and
-C(O)-alkyl;~~

~~or the R₁₋₂ and R₁₋₃ groups can join together to form a ring system selected from the group consisting of:~~



~~wherein n = 0, 1, 2, or 3;~~

R_{1-4} is selected from the group consisting of:

alkyl,

aryl,

alkylene-aryl,

heteroaryl,

alkylene-heteroaryl, and

alkyl, aryl, alkylene-aryl, heteroaryl, or alkylene-heteroaryl substituted by one or more substituents selected from the group consisting of:

halogen,

cyano,

nitro,

alkoxy,

dialkylamino,

alkylthio,

haloalkyl,

haloalkoxy,

alkyl, and

$$-N_3;$$


Y is selected from the group consisting of:

a bond,

-C(O)-,

-C(S)-,

$$-\text{S}(\text{O})_2-$$
$$-\text{S}(\text{O})_2-\text{N}(\text{R}_8)-,$$



-C(O)-O-,


-C(O)-N(R₈)-,

-C(S)-N(R₈)-,

-C(O)-N(R₈)-S(O)₂-,

-C(O)-N(R₈)-C(O)-,

-C(S)-N(R₈)-C(O)-,



-C(O)-C(O)-,

-C(O)-C(O)-O-, and

-C(=NH)-N(R₈)-;

~~R_A and R_B are each independently selected from the group consisting of:~~

~~hydrogen,~~

~~halogen,~~

~~alkyl,~~

~~alkenyl,~~

~~alkoxy,~~

~~alkylthio, and~~

~~-N(R₉)₂;~~

~~or when taken together, R_A and R_B form a fused aryl ring or heteroaryl ring containing one heteroatom selected from the group consisting of N and S, wherein the aryl or heteroaryl ring is unsubstituted or substituted by one or more R groups, or substituted by one R₃ group, or substituted by one R₃ group and one R group;~~

~~or when taken together, R_A and R_B form a fused 5 to 7 membered saturated ring, optionally containing one heteroatom selected from the group consisting of N and S, and unsubstituted or substituted by one or more R groups;~~

R is selected from the group consisting of:

halogen,
hydroxy,
alkyl,
alkenyl,
haloalkyl,
alkoxy,
alkylthio, and
-N(R₉)₂;

R₂ is selected from the group consisting of [[:]] alkyl, and alkylenyl-O-alkyl

~~-R₄,~~
~~-X'-R₄,~~
~~-X'-Y'-R₄, and~~
~~-X'-R₅;~~


R₃ is selected from the group consisting of:

-Z'-R₄,
-Z'-X'-R₄,
-Z'-X'-Y'-R₄, and
-Z'-X'-R₅;

X' is selected from the group consisting of alkylene, alkenylene, alkynylene, arylene, heteroarylene, and heterocyclylene, wherein the alkylene, alkenylene, and alkynylene groups can be optionally interrupted or terminated by arylene, heteroarylene or heterocyclylene and optionally interrupted by one or more -O- groups;

Y' is selected from the group consisting of:


-O-,
-S(O)₀₋₂-,
-S(O)₂-N(R₈)-,
-C(R₆)-,
-C(R₆)-O-,



Z' is a bond or -O-;

R₄ is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl, wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, mercapto, cyano, aryl, aryloxy, arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl, amino, alkylamino, dialkylamino, (dialkylamino)alkyleneoxy, and in the case of alkyl, alkenyl, alkynyl, and heterocyclyl, oxo;

R_5 is selected from the group consisting of:



R_6 is selected from the group consisting of =O and =S;

R₇ is C₂₋₇ alkylene;

R_8 is selected from the group consisting of hydrogen,

C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₁₋₁₀ alkoxy-C₁₋₁₀ alkylenyl, hydroxy-C₁₋₁₀ alkylenyl, heteroaryl-C₁₋₁₀ alkylenyl, and aryl-C₁₋₁₀ alkylenyl;

R₉ is selected from the group consisting of hydrogen and alkyl;

R₁₀ is C₃₋₈ alkylene;

A is selected from the group consisting of -O-, -C(O)-, -S(O)₀₋₂-, -CH₂-, and -N(R₄)-;


Q is selected from the group consisting of a bond, -C(R₆)-, -C(R₆)-C(R₆)-, -S(O)₂-, -C(R₆)-N(R₈)-W-, -S(O)₂-N(R₈)-, -C(R₆)-O-, -C(R₆)-S-, and -C(R₆)-N(OR₉)-;

V is selected from the group consisting of -C(R₆)-, -O-C(R₆)-, -N(R₈)-C(R₆)-, and -S(O)₂-;

W is selected from the group consisting of a bond, -C(O)-, and -S(O)₂-;

and a and b are each independently integers from 1 to 6 with the proviso that a + b is ≤ 7 ; or a pharmaceutically acceptable salt thereof.


3. (Canceled)
4. (Currently amended) A compound of the Formula (IV):



IV

wherein:

Z is $-\text{C}(=\text{N}-\text{O}-\text{R}_{1-2})-$ or



X is ~~selected from the group consisting of:~~

~~$-\text{CH}(\text{R}_9)-[\text{L}]$~~

~~$-\text{CH}(\text{R}_9)$ alkylene, and~~

~~$-\text{CH}(\text{R}_9)$ alkenylene,~~

~~wherein the alkylene and alkenylene are optionally interrupted by one or more O-~~
~~groups;~~

R₁₋₁ is selected from the group consisting of:

hydrogen,

alkyl,

aryl,

alkylene-aryl,

heteroaryl,

alkylene-heteroaryl, and

alkyl, aryl, alkylene-aryl, heteroaryl, or alkylene-heteroaryl substituted by one or
more substituents selected from the group consisting of:

halogen,

cyano,

nitro,

alkoxy,

dialkylamino,

alkylthio,

haloalkyl,

haloalkoxy,

alkyl,

$-\text{NH}-\text{SO}_2-\text{R}_{1-4}$,

$-\text{NH}-\text{C}(\text{O})-\text{R}_{1-4}$,

-NH-C(O)-NH₂,
-NH-C(O)-NH-R₁₋₄, and
-N₃;

R₁₋₂ and R₁₋₃ are independently selected from the group consisting of:


hydrogen,
alkyl,
~~alkenyl,~~
~~aryl,~~
~~arylalkylenyl,~~
~~heteroaryl,~~
~~heteroarylalkylenyl,~~
~~heterocyclyl,~~
~~heterocyclylalkylenyl,~~ and

~~alkyl, alkenyl, aryl, arylalkylenyl, heteroaryl, heteroarylalkylenyl, heterocyclyl, or~~
~~heterocyclylalkylenyl,~~ substituted by one or more substituents selected from the group
consisting of:

~~hydroxy,~~
~~alkyl,~~
~~haloalkyl,~~
~~hydroxyalkyl,~~
~~alkoxy,~~
~~dialkylamino,~~
~~-S(O)₀₋₂-alkyl,~~
~~-S(O)₀₋₂-aryl,~~
~~-NH-S(O)₂-alkyl,~~
~~-NH-S(O)₂-aryl,~~
~~haloalkoxy,~~
~~halogen,~~
~~cyano,~~

~~nitro,~~
~~aryl, and~~
~~heteroaryl~~[[,]];
~~heterocyclyl,~~
~~aryloxy,~~
~~arylalkyleneoxy,~~
~~C(O) O alkyl,~~
~~C(O) N(R₈)₂,~~
~~N(R₈) C(O) alkyl,~~
~~O (CO) alkyl, and~~
~~C(O) alkyl;~~

~~_____ or the R₁₋₂ and R₁₋₃ groups can join together to form a ring system selected from the group consisting of:~~



R₁₋₄ is selected from the group consisting of:

alkyl,
aryl,
alkylene-aryl,
heteroaryl,
alkylene-heteroaryl, and

alkyl, aryl, alkylene-aryl, heteroaryl, or alkylene-heteroaryl substituted by one or more substituents selected from the group consisting of:

halogen,
cyano,
nitro,
alkoxy,

dialkylamino,
alkylthio,
haloalkyl,
haloalkoxy,
alkyl, and
-N₃;

Y is selected from the group consisting of:


a bond,

-C(O)-,

-C(S)-,

-S(O)₂-,

-S(O)₂-N(R₈)-,



-C(O)-O-,


-C(O)-N(R₈)-,

-C(S)-N(R₈)-,

-C(O)-N(R₈)-S(O)₂-,

-C(O)-N(R₈)-C(O)-,

-C(S)-N(R₈)-C(O)-,



-C(O)-C(O)-,

-C(O)-C(O)-O-, and

-C(=NH)-N(R₈)-;

R is selected from the group consisting of:

halogen,

hydroxy,

alkyl,
alkenyl,
haloalkyl,
alkoxy,
alkylthio, and
-N(R₉)₂;

R₂ is selected from the group consisting of alkyl, and alkylenyl-O-alkyl

~~R₄,~~
~~X'-R₄,~~
~~X'-Y'-R₄, and~~
~~X'-R₅;~~

R₃ is selected from the group consisting of:

-Z'-R₄,
-Z'-X'-R₄,
-Z'-X'-Y'-R₄, and
-Z'-X'-R₅;


n' is an integer from 0 to 4;

m is 0 or 1; with the proviso that when m is 1, then n' is 0 or 1;

X' is selected from the group consisting of alkylene, alkenylene, alkynylene, arylene, heteroarylene, and heterocyclylene, wherein the alkylene, alkenylene, and alkynylene groups can be optionally interrupted or terminated by arylene, heteroarylene or heterocyclylene and optionally interrupted by one or more -O- groups;

Y' is selected from the group consisting of:


-O-,
-S(O)₀₋₂-,
-S(O)₂-N(R₈)-,
-C(R₆)-,
-C(R₆)-O-,
-O-C(R₆)-,



Z' is a bond or -O-;

R₄ is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl, wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, mercapto, cyano, aryl, aryloxy, arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl, amino, alkylamino, dialkylamino, (dialkylamino)alkyleneoxy, and in the case of alkyl, alkenyl, alkynyl, and heterocyclyl, oxo;

R₅ is selected from the group consisting of



R₆ is selected from the group consisting of =O and =S;

R₇ is C₂₋₇ alkylene;

R₈ is selected from the group consisting of hydrogen,
C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₁₋₁₀ alkoxy-C₁₋₁₀ alkylenyl, hydroxy-C₁₋₁₀ alkylenyl, heteroaryl-C₁₋₁₀ alkylenyl, and aryl-C₁₋₁₀ alkylenyl;

R₉ is selected from the group consisting of hydrogen and alkyl;

R₁₀ is C₃₋₈ alkylene;

A is selected from the group consisting of -O-, -C(O)-, -S(O)₀₋₂-, -CH₂-, and -N(R₄)-;

Q is selected from the group consisting of a bond, -C(R₆)-, -C(R₆)-C(R₆)-, -S(O)₂-, -C(R₆)-N(R₈)-W-, -S(O)₂-N(R₈)-, -C(R₆)-O-, -C(R₆)-S-, and -C(R₆)-N(OR₉)-;

V is selected from the group consisting of -C(R₆)-, -O-C(R₆)-, -N(R₈)-C(R₆)-, and -S(O)₂-;

W is selected from the group consisting of a bond, -C(O)-, and -S(O)₂-;

and a and b are each independently integers from 1 to 6 with the proviso that a + b is ≤ 7; or a pharmaceutically acceptable salt thereof.

5.-13. (Canceled)

14. (Previously presented) The compound or salt of claim 4 wherein m is 0.

15. (Previously presented) The compound or salt of claim 4 wherein n' is 0.

16. (Original) The compound or salt of claim 14 wherein m and n' are both 0.

17. (Previously presented) The compound or salt of claim 4, wherein R₃ is selected from

the group consisting of pyridin-3-yl, pyridin-4-yl, 5-(hydroxymethyl)pyridin-3-yl, and 2-ethoxyphenyl.

18. (Canceled)


19. (Currently amended) The compound or salt of claim [[2]] ~~18~~ wherein R₂ is selected from the group consisting of ~~hydrogen, hydroxymethyl, C₁₋₄ alkyl, and C₁₋₄ alkylenyl-O-C₁₋₄ alkyl~~ ~~C₁₋₄ alkyl-O-C₁₋₄ alkylenyl~~.

20. (Previously presented) The compound or salt of claim 2 wherein X is selected from the group consisting of -(CH₂)₁₋₆-, -CH₂C(CH₃)₂-, -CH₂C(CH₃)₂CH₂-, -(CH₂)₂OCH₂-, and -(CH₂)₃OCH₂-.

21. (Previously presented) The compound or salt of claim 2 wherein R₁₋₁ is selected from the group consisting of hydrogen, C₁₋₄ alkyl, and phenyl.

22. (Previously presented) The compound or salt of claim 2 wherein R₁₋₂ is selected from the group consisting of hydrogen, C₁₋₄ alkyl, benzyl, and pyridin-2-ylmethyl.

23. (Previously presented) The compound or salt of claim 2 wherein Z is -C(=N-O-R₁₋₂)-.

24. (Previously presented) The compound or salt of claim 2 wherein Z is 

25. (Currently amended) The compound or salt of claim 2 wherein R₁₋₃ is selected from the group consisting of hydrogen[[,]] and C₁₋₆ alkyl, ~~1-pyrrolidinyl, phenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, o-tolyl, m-tolyl, p-tolyl, and pyridin-3-yl.~~

26. (Previously presented) The compound or salt of claim 2 or 25 wherein Y is selected from the group consisting of:

-C(O)-,
-C(O)-O-,
-S(O)₂-,
-C(O)-N(R₈)-, and
-C(S)-N(R₈)-.

27. (Original) The compound or salt of claim 26 wherein R₈ is H or CH₃.

28. (Previously presented) A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 2 in combination with a pharmaceutically acceptable carrier.

29. (Withdrawn) A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or salt of claim 2 to the animal.

30. (Withdrawn) A method of treating a viral disease in an animal in need thereof comprising administering a therapeutically effective amount of a compound or salt of claim 2 to the animal.

31. (Withdrawn) A method of treating a neoplastic disease in an animal in need thereof comprising administering a therapeutically effective amount of a compound or salt of claims 2 to the animal.

32.-40. (Canceled)

41. (Currently amended) The compound or salt of claim 4 wherein R₂ is selected from the group consisting of:

hydrogen,

alkyl[[,]] and alkylenyl-O-alkyl
~~alkenyl,~~
~~aryl,~~
~~heteroaryl,~~
~~heterocyclyl,~~
~~alkylene-Y''-alkyl,~~
~~alkylene-Y''-aryl, and~~
~~alkyl or alkenyl substituted by one or more substituents selected from the group~~
~~consisting of:~~

~~hydroxy,~~
~~halogen,~~
~~-N(R₁₁)₂,~~
~~-C(O)-C₁₋₁₀-alkyl,~~
~~-C(O)-O-C₁₋₁₀-alkyl,~~
~~-N(R₁₁)-C(O)-C₁₋₁₀-alkyl,~~
~~aryl,~~
~~heteroaryl,~~
~~heterocyclyl,~~
~~-C(O)-aryl, and~~
~~-C(O)-heteroaryl;~~

wherein:

~~Y'' is -O- or -S(O)₀₋₂-; and~~

~~R₁₁ is selected from the group consisting of hydrogen, C₁₋₁₀-alkyl, and C₂₋₁₀-alkenyl.~~

42. (Currently amended) The compound or salt of claim 4 wherein R₂ is selected from the group consisting of ~~hydrogen, hydroxymethyl,~~ C₁₋₄ alkyl [[,]] and C₁₋₄ alkylenyl-O-C₁₋₄ ~~alkylenyl~~.

43. (Previously presented) The compound or salt of claim 4 wherein X is selected from the group consisting of -(CH₂)₁₋₆-, -CH₂C(CH₃)₂-, -CH₂C(CH₃)₂CH₂-, -(CH₂)₂OCH₂-, and -


$(\text{CH}_2)_3\text{OCH}_2-$.

44. (Previously presented) The compound or salt of claim 4 wherein R_{1-1} is selected from the group consisting of hydrogen, C_{1-4} alkyl, and phenyl.

45. (Previously presented) The compound or salt of claim 4 wherein R_{1-2} is selected from the group consisting of ~~hydrogen~~, C_{1-4} alkyl, benzyl[[,]] and pyridin-2-ylmethyl.

46. (Previously presented) The compound or salt of claim 4 wherein Z is $-\text{C}(=\text{N}-\text{O}-\text{R}_{1-2})-$.

47. (Previously presented) The compound or salt of claim 4 wherein Z is



48. (Previously presented) The compound or salt of claim 4 wherein R_{1-3} is ~~selected from the group consisting of hydrogen, C_{1-6} alkyl, 1-pyrrolidinyl, phenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, *o*-tolyl, *m*-tolyl, *p*-tolyl, and pyridin-3-yl.~~

49. (Previously presented) The compound or salt of claim 4 wherein Y is selected from the group consisting of:

$-\text{C}(\text{O})-$,

$-\text{C}(\text{O})-\text{O}-$,

$-\text{S}(\text{O})_2-$,

$-\text{C}(\text{O})-\text{N}(\text{R}_8)-$, and

$-\text{C}(\text{S})-\text{N}(\text{R}_8)-$.

50. (Previously presented) The compound or salt of claim 49 wherein R_8 is H or CH_3 .


51.-72. (Canceled)

73. (Previously presented) A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 4 in combination with a pharmaceutically acceptable carrier.

74. (Withdrawn) A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or salt of claim 4 to the animal.


75.-78. (Canceled)

79. (New) A compound of the Formula (IV):



wherein:

Z is $-C(=N-O-R_{1-2})-$ or



X is $-CH(R_9)-$;

R_{1-1} is selected from the group consisting of:

hydrogen,
alkyl, and
aryl;

R_{1-2} and R_{1-3} are independently selected from the group consisting of:

hydrogen,
alkyl,
alkenyl-O-alkyl, and

alkyl substituted by one or more substituents selected from the group consisting of aryl and heteroaryl;

Y is selected from the group consisting of:

a bond,
-C(O)-,
-S(O)₂-,
-S(O)₂-N(R₈)-,
-C(O)-O-, and
-C(O)-N(R₈)-;

R₂ is selected from the group consisting of: alkyl, and alkylene-O-alkyl;

R₃ is -Z'-R₄;

Z' is a bond;

n' is 0 or 1;

m is 0 or 1;

R₄ is selected from the group consisting of: hydrogen, aryl and heteroaryl, wherein the aryl and heteroaryl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, mercapto, cyano, aryl, aryloxy, arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl, amino, alkylamino, dialkylamino, (dialkylamino)alkyleneoxy, and in the case of alkyl, alkenyl, alkynyl, and heterocyclyl, oxo; and

R₈ is selected from the group consisting of hydrogen, or C₁₋₁₀ alkyl;
or a pharmaceutically acceptable salt thereof.

80. (New) A compound selected from the groups consisting of:

N-[4-(4-Amino-2-propyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl]-*N*-methoxyacetamide;

1-[4-(4-Amino-2-propyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl]-1-methoxyurea;

N-[4-(4-Amino-2-propyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl]-*N*-methoxy-methanesulfonamide;

1-[4-(4-Amino-2-propyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)-butyl]-methoxy-3-phenylurea;

N-[4-(4-Amino-2-propyl-1*H*-imidazo[4,5-*c*]quinolin-1-methylbutyl]-*N*-methoxy-acetamide;

1-[4-(4-Amino-2-propyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)-1-methylbutyl]-1-methoxy-3-phenylurea;
1-[4-(4-Amino-2-propyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)-1-methylbutyl]-3-ethyl-1-methoxyurea;
N-[4-(4-Amino-2-ethoxymethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)-1-methylbutyl]-*N*-methoxymethanesulfonamide;
5-(4-Amino-7-phenyl-2-propyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)pentan-2-one-*O*-methyloximine;
1-[4-(4-Amino-7-phenyl-2-propyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)-1-methylbutyl]-3-isopropyl-1-methoxyurea;
4-(4-Amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)-1-phenylbutan-1-one-oxime;
4-(4-Amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)-1-phenylbutan-1-one-*O*-methyloxime;
5-(4-Amino-2-methyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)pentan-2-one-oxime;
5-(4-Amino-2-methyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)pentan-2-one-*O*-benzyloxime;
5-(4-Amino-2-methyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)pentan-2-one-*O*-methyloxime;
5-(4-Amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)pentan-2-one-*O*-methyloxime;
5-(4-Amino-2-ethoxymethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)pentan-2-one-oxime;
5-(4-Amino-2-ethoxymethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)pentan-2-one-*O*-methyloxime hydrochloride;
5-(4-Amino-2-ethoxymethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)pentan-2-one-*O*-benzyloxime hydrochloride;
1-(4-Amino-2-propyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)-6-methylheptan-4-one-oxime;
1-(4-Amino-2-propyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)decan-4-one-oxime;
5-(4-Amino-2-methyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)-4,4-dimethylpentan-2-one-*O*-methyl-oxime;
5-(4-Amino-2-propyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)-4,4-dimethylpentan-2-one-*O*-methyloxime;
5-(4-Amino-1*H*-imidazo[4,5-*c*]quinolin-1-yl)-4,4-dimethylpentan-2-one-*O*-methyloxime;
(1*E,Z*)-4-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butanal-*O*-methyloxime;
N-[4-(4-Amino-2-propyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl]-*N*-hydroxyacetamide;
N-[4-(4-Amino-2-propyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl]-*N*-hydroxy-*N'*-isopropylurea;
4-(4-Amino-2-methyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butanal-*O*-methyloxime;
N-[4-(4-Amino-2-methyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl]-*N*-methoxyurea;
N-[4-(4-Amino-2-methyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl]-*N*-methoxymethanesulfonamide;

1-[4-Amino-2-(ethoxymethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butan-2-one-*O*-methyloxime;
N-{4-[4-Amino-2-(ethoxymethyl)-1*H*-imidazo[4,5-*c*][1,5]naphthyridin-1-yl]-1-methylbutyl}-*N'*-
isopropyl-*N*-methoxyurea;
N-[4-(4-Amino-2-propyl-6,7,8,9-tetrahydro-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl]-*N*-hydroxy-*N'*-
isopropylurea;
N-[3-(4-Amino-2-ethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl]-*O*-methylhydroxylamine;
N-(3-(4-amino-2-ethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl)-*N*-methoxyhexanamide
N-(3-(4-amino-2-ethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl)-*N*-methoxycyclohexanecarboxamide;
N-(3-(4-amino-2-ethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl)-*N*-methoxy-2-methylbenzamide;
N-(3-(4-amino-2-ethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl)-2-chloro-*N*-methoxybenzamide;
N-(3-(4-amino-2-ethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl)-3-chloro-*N*-methoxybenzamide;
N-(3-(4-amino-2-ethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl)-4-chloro-*N*-methoxybenzamide;
N-(3-(4-amino-2-ethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl)-*N*-methoxynicotinamide;
N-(3-(4-amino-2-ethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl)-*N*-methoxy-1-(*m*-
tolylsulfonyl)methanamide;
N-(3-(4-amino-2-ethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl)-*N*-methoxy-1-(*m*-
tolylsulfonyl)methanamide;
N-(3-(4-amino-2-ethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl)-*N*-methoxy-1-(*o*-
tolylsulfonyl)methanamide;
N-(3-(4-amino-2-ethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl)-*N*-methoxy-1-tosylmethanamide;
N-(3-(4-amino-2-ethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl)-1-(2-chlorophenylsulfonyl)-*N*-
methoxymethanamide;
N-(3-(4-amino-2-ethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl)-1-(3-chlorophenylsulfonyl)-*N*-
methoxymethanamide;
N-(3-(4-amino-2-ethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl)-1-(4-chlorophenylsulfonyl)-*N*-
methoxymethanamide;
N-(3-(4-amino-2-ethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl)-1-((1*S*,4*S*)-7,7-dimethyl-2-
oxobicyclo[2.2.1]heptan-1-yl)-*N*-methoxymethanesulfonamide;
1-(3-(4-amino-2-ethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl)-1-methoxy-3,3-dimethylthiourea;

1-(3-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl)-3-cyclohexyl-1-methoxyurea;
1-(3-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl)-1-methoxy-3-m-tolylurea;
1-(3-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl)-1-methoxy-3-o-tolylurea;
1-(3-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl)-1-methoxy-3-(pyridin-3-yl)thiourea;
N-(3-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl)-N-methoxymorpholine-4-carboxamide;
1-(3-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl)-1-methoxy-3-methyl-3-phenylurea;
N-(3-(4-amino-7-bromo-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl)-N-methoxyacetamide;
N-(3-(4-amino-7-phenyl-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl)-N-methoxyacetamide;
N-(3-(4-amino-2-propyl-7-(pyridin-3-yl)-1H-imidazo[4,5-c]quinolin-1-yl)butyl)-N-methoxyacetamide;
N-(3-(4-amino-2-propyl-7-(pyridin-4-yl)-1H-imidazo[4,5-c]quinolin-1-yl)butyl)-N-methoxyacetamide;
N-(3-(4-amino-7-(2-hydroxyphenyl)-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl)-N-methoxyacetamide;
N-(3-(4-amino-7-(3-hydroxyphenyl)-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl)-N-methoxyacetamide;
3-(4-amino-1-(3-(N-methoxyacetamido)butyl)-2-propyl-1H-imidazo[4,5-c]quinolin-7-yl)benzamide;
or a pharmaceutically acceptable salt thereof.